An ancient herbal root with weak hormone-like and blood-vessel-relaxing activity. Its best-supported use is reducing how much alcohol heavy drinkers consume in a sitting, although they do not report wanting to drink less. Evidence for menopausal, heart, and blood-sugar uses is weaker. A real but modest signal for moderating drinking; otherwise promising yet unproven. (Full Review)

Protocol

Standardized Extract

Defined isoflavone dose

For alcohol reduction: single ~2 g dose (~520 mg isoflavones), or ~250 mg isoflavones three times daily over 4 weeks

Best Time of Day

~2–2.5 hours before drinking

For general supplementation no superior time is established; with food may reduce stomach upset

Dosing Frequency

Split dosing across the day

Short half-life (~1–4 hours) and poor bioavailability argue against a single daily dose when sustained exposure is the goal

Time to effect

Alcohol Reduction

Within a single session

Effects observed within hours when dosed beforehand

Menopausal Support

Weeks of consistent use

Typically required before any change, paralleling the phytoestrogen literature

Cardiovascular Support

Weeks of consistent use

Typically required before any change in symptom support

Benefits

Medium: Reduction in Alcohol Consumption

Low: Relief of Menopausal Hot Flashes; Cardiovascular and Anginal Symptom Support; Blood-Sugar and Metabolic Support

Speculative: Bone and Liver Protection

Contraindications

Pregnant or breastfeeding individuals

Active or prior estrogen-sensitive cancer

Significant liver disease

Bleeding disorders or scheduled surgery (stop at least 2 weeks prior)

Children (no safety data)

Key Interactions

Diabetes medications (e.g., metformin, sulfonylureas such as glipizide, insulin)

Antihypertensive drugs (e.g., ACE inhibitors such as lisinopril, calcium-channel blockers such as amlodipine)

Anticoagulant and antiplatelet drugs (e.g., warfarin, clopidogrel, aspirin)

Tamoxifen and hormone therapies / oral contraceptives

Methotrexate and drugs cleared by CYP enzymes

OTC agents: NSAIDs such as ibuprofen, antacids, alcohol-containing products

Supplements with additive effects (blood-pressure-lowering, blood-glucose-lowering, antiplatelet, other phytoestrogens)

Risk & Side Effects

Low: Liver Injury (Hepatotoxicity); Hormone-Sensitive Condition Stimulation; Increased Bleeding Tendency

Speculative: Acetaldehyde Accumulation and Cancer Concern; Injection-Related Adverse Events

Monitoring

Marker	Target	Why
ALT (alanine aminotransferase)	< 25 U/L (men), < 22 U/L (women)	Detects early liver-cell stress from the rare hepatotoxicity risk
AST (aspartate aminotransferase)	< 25 U/L	Complements ALT in screening for liver injury
Blood pressure	< 120/80 mmHg	Tracks the additive blood-pressure-lowering effect for safety and benefit
Fasting glucose	70–85 mg/dL	Monitors additive blood-sugar lowering when used for metabolic support
HbA1c	< 5.4%	Reflects 3-month average blood sugar for metabolic-use monitoring

Cadence: Baseline, then roughly 4–8 weeks after starting, then every 3–6 months during continued use; earlier if symptoms of liver trouble appear

Qualitative Assessment

Reduction in number of drinks per occasion or per week (the primary success marker for alcohol-reduction use)
Frequency and intensity of menopausal hot flashes, where that is the goal
General energy, absence of digestive upset, and no symptoms suggestive of liver trouble
Subjective tolerability and adherence

Kudzu for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment